Since there is no abstract, we provide the first paragraph
Beyond “classic” prognostic factors and HER2/ER status  there is an urgent need for molecular class II prognostic and class III predictive biomarkers not only for breast cancer but also for most solid cancers [2-5]. Currently, this goal appears to be achievable for hereditary breast cancer [6-8]. However, despite efforts and use of high-throughput technologies, no robust prognostic biomarker has been validated for wide clinical use in sporadic breast cancer. Could micrometastatic disease in lymph nodes be used as prognostic marker?